TP53 and myelodysplastic syndrome: In a recent multicenter retrospective study from China (70), TP53 mutation (HR = 17.339, p =.033) and relapse within 1 year posttransplantation (HR = 6.261, p =.026) were identified as independent risk factors when HMAs/VEN was used in relapsed AML or MDS patients.